Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors.

The influence of physicochemical properties, including lipophilicity, H-bonding capacity and molecular size and shape descriptors on brain uptake has been investigated using a selection of marketed CNS and CNS-inactive drugs. It is demonstrated that the polar surface area of a drug can be used as a suitable descriptor for the drugs' H-bonding potential. A combination of a H-bonding and a molecular size descriptor, i.e., the major components of lipophilicity and permeability, avoiding knowledge of distribution coefficients, is proposed to estimate brain penetration potential of new drug candidates. Previously reported experimental surface activity data appear to be strongly correlated to molecular size of the drug compounds. Present analysis offers a modern basis for property-based design and targeting of CNS drugs.

[1]  M. Abraham,et al.  On the partition of ampholytes: application to blood-brain distribution. , 1997, Journal of pharmaceutical sciences.

[2]  J. Hawkinson,et al.  Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDA receptor. , 1997, Journal of medicinal chemistry.

[3]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[4]  F. Lombardo,et al.  Computation of brain-blood partitioning of organic solutes via free energy calculations. , 1996, Journal of medicinal chemistry.

[5]  G Folkers,et al.  Review of theoretical passive drug absorption models: historical background, recent developments and limitations. , 1996, Pharmaceutica acta Helvetiae.

[6]  K. Nakamura,et al.  Thermodynamic aspects of hydrophobicity and the blood-brain barrier permeability studied with a gel filtration chromatography. , 1996, Journal of medicinal chemistry.

[7]  K. Marsh,et al.  Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption. , 1996, Journal of medicinal chemistry.

[8]  D. Begley,et al.  The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.

[9]  Han van de Waterbeemd,et al.  Estimation of Caco‐2 Cell Permeability using Calculated Molecular Descriptors , 1996 .

[10]  K. Luthman,et al.  Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.

[11]  Harpreet S. Chadha,et al.  Hydrogen-bonding. Part 36. Determination of blood brain distribution using octanol-water partition coefficients. , 1995, Drug design and discovery.

[12]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[13]  Peter L. Bonate,et al.  Animal models for studying transport across the blood-brain barrier , 1995, Journal of Neuroscience Methods.

[14]  Hugo Kubinyi,et al.  The Physicochemical Significance of Topological Parameters. A Rebuttal , 1995 .

[15]  Oleg A. Raevsky,et al.  H-BOND CONTRIBUTION TO OCTANOL-WATER PARTITION COEFFICIENTS OF POLAR COMPOUNDS , 1995 .

[16]  Bernard Testa,et al.  Lipophilicity and hydrogen-bonding capacity of H1-antihistaminic agents in relation to their central sedative side-effects , 1994 .

[17]  Harpreet S. Chadha,et al.  Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. , 1994, Journal of pharmaceutical sciences.

[18]  C R Ganellin,et al.  Predicting the brain-penetrating capability of histaminergic compounds. , 1994, Drug design and discovery.

[19]  P. Leeson,et al.  3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. , 1994, Journal of medicinal chemistry.

[20]  D. Barlow,et al.  The design of peptide analogues for improved absorption , 1994 .

[21]  A. Seelig,et al.  A method to determine the ability of drugs to diffuse through the blood-brain barrier. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Michael H. Abraham,et al.  Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes , 2010 .

[23]  R. Broadwell.  Transcytosis of Macromolecules through the Blood—Brain Fluid Barriers in Vivo , 1993 .

[24]  W. Pardridge,et al.  Brain drug delivery and blood–Brain barrier transport , 1993 .

[25]  M. Kansy,et al.  Hydrogen-Bonding Capacity and Brain Penetration , 1992, Chimia (Basel).

[26]  Bernard Testa,et al.  Polar intermolecular interactions encoded in partition coefficients: an indirect estimation of hydrogen-bond parameters of polyfunctional solutes , 1992 .

[27]  Oleg A. Raevsky,et al.  Complete Thermodynamic Description of H‐Bonding in the Framework of Multiplicative Approach , 1992 .

[28]  Donald W. Miller,et al.  Brain uptake of drugs : the influence of chemical and biological factors , 1992 .

[29]  A. Seelig,et al.  Substance P and Antagonists , 1991 .

[30]  C G Wermuth,et al.  GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative. , 1991, Journal of medicinal chemistry.

[31]  W. R. Lieb,et al.  Role of hydrogen bonding in general anesthesia. , 1991, Journal of pharmaceutical sciences.

[32]  N el Tayar,et al.  Partitioning of solutes in different solvent systems: the contribution of hydrogen-bonding capacity and polarity. , 1991, Journal of pharmaceutical sciences.

[33]  C. Lipinski,et al.  Physical parameters for brian uptake: optimizing log P, log D and pKa of T H A , 1991 .

[34]  A. Seelig.  Substance P and antagonists. Surface activity and molecular shapes. , 1990, Biochimica et biophysica acta.

[35]  S. P. Gupta,et al.  QSAR studies on drugs acting at the central nervous system , 1989 .

[36]  N. Bodor,et al.  A new method for the estimation of partition coefficient , 1989 .

[37]  R Griffiths,et al.  Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. , 1988, Journal of medicinal chemistry.

[38]  A. Leo,et al.  Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.

[39]  Bernard Testa,et al.  The parametrization of lipophilicity and other structural properties in drug design , 1987 .

[40]  J. Leysen,et al.  Optimal Conditions for [3H]Apomorphine Binding and Anomalous Equilibrium Binding of [3H]Apomorphine and [3H]Spiperone to Rat Striatal Membranes: Involvement of Surface Phenomena Versus Multiple Binding Sites , 1981, Journal of neurochemistry.

[41]  P. Seiler,et al.  Steric and lipophobic components of the hydrophobic fragmental constant. , 1981, Arzneimittel-Forschung.

[42]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[43]  G. L. Tong,et al.  Structural requirements for centrally acting drugs. I. , 1973, Journal of pharmaceutical sciences.

[44]  A. Leo,et al.  Partition coefficients and their uses , 1971 .

[45]  Merlis Jk.  Anatomical and physiological aspects. , 1954 .